在最近的小次皮层中风中最佳使用抗血栓剂,伴随着心房动
Minwoo Lee1,2, Mi-Sun Oh1, Kyung-Ho Yu1
1Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea.
European stroke journal
|May 28, 2024
概括
与抗血小板药物 (APT) 相比,抗凝剂 (AC) 在最近发生小皮下心脏病发作 (RSSI) 和心房动 (AF) 的患者中表现出更好的结果. 组合疗法还降低了中风复发风险,而单独使用APT.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 最近的小皮下心脏病发作 (RSSI) 和心房动 (AF) 是一个复杂的临床挑战.
- 对抗凝血剂 (AC) 和抗血小板剂 (APT) 的比较疗效和安全性进行评估对于最佳的患者管理至关重要.
研究的目的:
- 评估AC与APT在RSSI和AF患者中的有效性和安全性.
- 为了比较不同治疗策略之间的出血,中风复发和死亡率的风险.
主要方法:
- 分析了未来的多中心中风注册表数据.
- 倾向性得分与AC组,APT组和组合疗法组的平衡基线特征相匹配.
- 多变量考克斯回归计算了关键结果的调整危险比率.
主要成果:
- 与单独抗血小板 (APT) 治疗相比,单独抗血小板 (AC) 治疗显著降低了严重出血,中风复发和全因死亡的风险.
- 组合疗法 (AC + APT) 显示,中风复发的风险低于单独使用APT.
- 虽然出血事件的发生率在各组之间是可比的,但AC单一治疗产生了更好的整体临床结果.
结论:
- 与抗血小板药物 (APT) 相比,抗凝固剂 (AC) 在最近出现小皮下心脏病发作 (RSSI) 和心房动 (AF) 的患者中提供更好的临床结果.
- 与AC和APT的联合治疗与APT单一治疗相比,与中风复发的风险降低有关.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
681
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
681
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
Clot Retraction and Fibrinolysis
5.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.5K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K


